Información del producto
FOXA1 antibody
Información adicional
Size
100µg
Storage Conditions
PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
Applications
ELISA, WB, IHC
Target
FOXA1
Research Area
Epigenetics, Signal Transduction, Metabolism, Developmental biology, Neuroscience, Stem Cells
Form
liquid
Recomended Dilution
IHC: 1:50 - 1:200
WB: 1:500 - 1:2000
WB: 1:500 - 1:2000
Type Clonality
polyclonal
Immunogen
forkhead box A1
Minimum Purity
≥95% as determined by SDS-PAGE
Synonyms
Hepatocyte nuclear factor 3-alpha (HNF-3-alpha, HNF-3A)|Forkhead box protein A1|Transcription factor 3A (TCF-3A)|FOXA1|HNF3A|TCF3A
Host
Rabbit
UniProt ID
P55317
Gene ID
3169
Purification
Immunogen affinity purified
Iso type
IgG
Reactivity
Human, Mouse
Observed MW
50 kDa
Background
FOXA1 and FOXA2 seem to have at least in part redundant roles(By similarity). Modulates the transcriptional activity of nuclear hormone receptors. Is involved in ESR1-mediated transcription
Transcription factor that is involved in embryonic development, establishment of tissue-specific gene expression and regulation of gene expression in differentiated tissues. Is thought to act as a 'pioneer' factor opening the compacted chromatin for other
binds to the RPRM promter and is required for the estrogen-induced repression of RPRM. Involved in regulation of apoptosis by inhibiting the expression of BCL2. Involved in cell cycle regulation by activating expression of CDKN1B, alone or in conjunction
required for ESR1 binding to the NKX2-1 promoter in breast cancer cells
Transcription factor that is involved in embryonic development, establishment of tissue-specific gene expression and regulation of gene expression in differentiated tissues. Is thought to act as a 'pioneer' factor opening the compacted chromatin for other
binds to the RPRM promter and is required for the estrogen-induced repression of RPRM. Involved in regulation of apoptosis by inhibiting the expression of BCL2. Involved in cell cycle regulation by activating expression of CDKN1B, alone or in conjunction
required for ESR1 binding to the NKX2-1 promoter in breast cancer cells